MENU
NOV 09, 2017 10:00 AM PST

Eliminating inherent genome editing bottlenecks in iPSCs to build physiologically relevant disease models

Speaker
  • Staff Scientist, Thermo Fisher Scientific
    Biography
      Dr. Erik Willems was trained as a stem cell biologist in Brussels, Belgium where he obtained his PhD in 2007, after which he soon relocated to San Diego, California to develop his expertise in the use of pluripotent stem cells in high throughput screening assays for understanding the basic biology and disease of the developing heart at the Sanford Burnham Prebys Medical Discovery Institute. Dr. Willems then pursued his passion for the development of biotechnology tools and applications and joined Thermo Fisher Scientific in Carlsbad, California where he - as a Manager in the Cell Biology group - currently leads a team focused on pluripotent stem cell-based customer driven projects and product applications, including characterization, reprogramming, genome editing, differentiation and disease modeling with a focus on drug discovery applications. Now in the stem cell field for over 15 years, Dr. Willems published numerous peer reviewed articles including in high impact journals such as Cell Stem Cell. His key expertise includes pluripotent stem cell biology, differentiation, genome editing, high throughput screening and drug discovery.

    Abstract

    Therapeutic development for human diseases continues to face obstacles, particularly in translating targets or compounds identified by in vitro screening campaigns to valid targets or efficacious and safe compounds once tested in humans.  Here we discuss strategies that leverage induced pluripotent stem cells (iPSCs) to increase the relevance of human cell models for these in vitro approaches.  We review current advances in genome engineering to pivot from challenges with delivery, identification and selection and subsequent clonal outgrowth by leveraging tools to consistently and reliably generate knock-out and knock-in models for use in target or compound identification.  Specifically, we demonstrate this approach with iPSCs to build isogenic disease models, which can be further differentiated to various cell types of interest such as cardiomyocytes and dopaminergic neurons to model disease and are more directly related to a disease area than commonly used immortalized cell lines.  We expect strategies combining genome engineering and stem cells to provide platforms for more robust disease models that will provide more predictable translation of in vitro to in vivo results.


    Show Resources
    NOV 09, 2017 10:00 AM PST

    Eliminating inherent genome editing bottlenecks in iPSCs to build physiologically relevant disease models


    Specialty

    Cell Biology

    Biotechnology

    Molecular Biology

    Genetics

    Cell Culture

    Cancer Research

    Biomarkers

    Biochemistry

    Gene Expression

    Immunology

    Genomics

    Stem Cell Technologies

    Dna

    Gene Sequencing

    Clinical Research

    Geography

    North America43%

    Europe28%

    Asia14%

    South America8%

    Africa8%

    Registration Source

    Website Visitors100%

    Job Title

    Student20%

    Research Scientist17%

    Scientist15%

    Educator/Faculty13%

    Post Doc6%

    Medical Doctor/Specialist5%

    Facility/Department Manager4%

    Medical Laboratory Technician4%

    Executive3%

    Lab Management3%

    Biologist2%

    Clinical Laboratory Scientist2%

    Consultant2%

    Engineer1%

    Chemist1%

    Veterinarian1%

    Organization

    Academic Institution19%

    Research Institute8%

    Biotech Company4%

    Medical School3%

    Clinical Laboratory3%

    Government3%

    Hospital2%

    Ambulatory Care2%

    Life Science Company2%

    Medical Center1%

    Dental Office1%

    Non-Profit Organization1%

    Independent Laboratories1%

    Medical Device Company1%

    Other3%


    Show Resources
    Show Resources
    Attendees
    • See more